Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells 7,000 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 7,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the sale, the executive vice president now directly owns 118,469 shares in the company, valued at $5,262,392.98. This trade represents a 5.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Rong Zhou also recently made the following trade(s):

• On Tuesday, November 12th, Rong Zhou sold 6,893 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $48.88, for a total transaction of $336,929.84.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $40.85 on Wednesday. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 13.62, a PEG ratio of 0.87 and a beta of 0.78. The business’s 50 day moving average is $47.02 and its two-hundred day moving average is $44.64. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Victory Capital Management Inc. lifted its holdings in Amphastar Pharmaceuticals by 10.9% in the third quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock valued at $10,605,000 after acquiring an additional 21,530 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $11,070,000. Intech Investment Management LLC purchased a new stake in Amphastar Pharmaceuticals during the second quarter worth about $426,000. XTX Topco Ltd acquired a new position in Amphastar Pharmaceuticals during the third quarter worth about $674,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $785,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on AMPH. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective for the company. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $60.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.